Ongoing, recruitingTherapeutic use (Phase IV)Interventional

Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic use (Phase IV)

Sponsor

Charite Universitaetsmedizin Berlin KöR

Enrolment target

104

Start

13 Oct 2023

Proportion of subjects achieving disease remission defined as Ankylosing Spondylitis Disease Activity Score (ASDAS)CRP<1.3 at week 16 from baseline.

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.